A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania With Mixed Features in Bipolar-I Disorder (BALSAM-3)

ReclutandoFase 3ClinicalTrials.gov

ID: NCT06929273Tipo: INTERVENTIONALInicio: 18 de jul de 2025Fin estimado: 13 de jun de 2028

Traducción no disponible, mostrando original

Resumen

This is a phase 3, open-label extension study to assess the long-term safety of KarXT for the treatment of mania or mania with mixed features in Bipolar-I disorder (BP-I) The primary objective of the study is to evaluate the long-term safety and tolerability of KarXT in the treatment of participants with mania or mania with mixed features associated with BP-I.

Elegibilidad

Edad mínima: 18 YearsEdad máxima: 65 YearsSexo: ALL

Criterios de inclusión

Participants who participated in double-blind placebo-controlled study (CN0120036, CN0120037, or CN0120046):
a. Participants must have completed treatment period of parent study.
De novo participants who did not participate in double-blind placebo-controlled studies:
Participants must have primary diagnosis of Bipolar-I disorder established by a comprehensive psychiatric evaluation based on DSM-5-TR criteria and confirmed by the Mini International Neuropsychiatric Interview (MINI, v7.0.2), with symptoms of mania or mixed mania.
Participants must have Young Mania Rating Scale (YMRS) score of ≥ 14 at Screening and at baseline.
Participants must have CGI-BP score of ≥ 3 at Screening and at baseline.
Participants does not require hospitalization for acute mania.

Criterios de exclusión

Participants who participated in double-blind placebo-controlled study (CN0120036, CN0120037, or CN0120046):
a. Discontinuation from any KarXT parent studies.
De novo participants who did not participate in double-blind placebo-controlled studies:
All participants with a risk for suicidal behavior at baseline as determined by Investigator's clinical assessment or history of suicidal behavior as assessed on C-SSRS.
Participants must not have primary diagnosis of BP-I with rapid cycling (ie, ≥ 4 distinct mood episodes in one year).
Participants must not have any primary DSM-5-TR disorder other than BP-I with mania or mania with mixed features within 12 months before Screening (confirmed using MINI version 7.0.2 at Screening), including BP-I with depression, (previous 3 months only), Bipolar-II disorder, major depressive disorder, borderline personality disorder, and primary psychotic disorder, with the exception of mild anxiety disorders.
Individual has a DSM-5-TR diagnosis of moderate to severe substance use disorder (except tobacco use disorder) within the 12 months before Screening (confirmed using MINI version 7.0.2 at Screening), or current use as determined by urine toxicology screen or alcohol test.
Participants must not have history of irritable bowel syndrome (with or without constipation) or serious constipation requiring treatment within the last 6 months.
Participants must not have history or high risk of urinary retention, gastric retention, or untreated narrow-angle glaucoma.

Intervenciones

drug

KarXT

Specified dose on specified days

drug

Lithium

Therapeutic dose

drug

Valproate

Therapeutic dose

drug

Lamotrigine

Therapeutic dose

Ubicaciones

Local Institution - 0128

ABB, Buenos Aires F.D., Argentina

Site 0128

NOT_YET_RECRUITING

Local Institution - 0127

Córdoba, Argentina

Site 0127

NOT_YET_RECRUITING

Local Institution - 0126

Mendoza, Argentina

Site 0126

NOT_YET_RECRUITING

Patrocinadores

PrincipalBristol-Myers Squibb

Contactos

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

CONTACT

Clinical.Trials@bms.com 855-907-3286

First line of the email MUST contain NCT # and Site #.

CONTACT

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase 3, Open-label Extension Study to Assess the Long-... | EligiMed